Blockade of the protein–protein interaction between the transmembrane protein
programmed cell death protein 1 (PD‐1) and its ligand PD‐L1 has emerged as a promising …

Tumor immunotherapy has made great progress in recent years. In the tumor
microenvironment, the binding of PD-1 and its ligand PD-L1 can promote tumor immune …

Blockade the interaction of the programmed cell death protein 1 (PD-1) and its ligand,
programmed death-ligand 1 (PD-L1) can prevent immune evasion of tumor cells and …

Several monoclonal antibodies targeting the programmed cell death-1/programmed cell
death-ligand 1 (PD-1/PD-L1) pathway have been used successfully in anticancer …

With the successful clinical application of anti-programmed cell death-1 (PD-1)/programmed
cell death-ligand 1 (PD-L1) monoclonal antibodies (mAb), targeting the PD-1/PD-L1 …

The clinical success of inhibitors targeting the PD-1/PD-L1 pathway has made this an active
field in cancer immunotherapy. Currently, most drugs targeting this pathway are monoclonal …

Blockade of programmed cell death ligand-1 (PD-L1) restores T-cell activity and enhances
anti-tumor immunity. Screening a phage-displayed peptide library for peptides that …

Peptides have potential to be developed into immune checkpoint inhibitors, but the target
interfaces are difficult to inhibit. Here, we explored an approach to mimic the binding surface …

Blocking the activity of the programmed cell death protein 1 (PD-1) inhibitory receptor with
therapeutic antibodies against either the ligand (PD-L1) or PD-1 itself has proven to be an …

Highlights•Cancer immunotherapy was chosen as the most important breakthrough in 2013
by the Science.•Two monoclonal antibodies targeting the PD-1/PD-L1 pathway have been …